Search

Displaying results 521 - 530 of 9699 in total
  1. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. … [L13290] It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.

  2. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication ...

    Mixtures: VELMETIA LPProducts: Sitagliptin 1A Pharma 25 mg – Filmtabletten, Sitagliptin 1A Pharma 50 mg – Filmtabletten
  3. Drug

    Clotrimazole

    go.drugbank.com/drugs/DB00257
    ApprovedInvestigationalVet approved

    This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s [A174094]. … As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers [A174094].

    Mixtures: SAEROGENTA-A CREAM, Creobic DA (Double Action) CreamProducts: Votriza-AL, CLOTRIMAZOL AL 1%
  4. Drug

    Brimonidine

    go.drugbank.com/drugs/DB00484
    ApprovedInvestigational

    [A178951] It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 adrenoceptors over alpha-1 receptors. … [A179002] Brimonidine displays a higher selectivity toward the alpha-2 adrenergic receptors than [clonidine] or [apraclonidine], which are also alpha-2 adrenergic agonists.

    Mixtures: Tim-Brim-Dor-Lat
  5. Drug

    Alefacept

    go.drugbank.com/drugs/DB00092
    ApprovedWithdrawn

    Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of

    Categories: CD2-directed LFA-3/Fc Fusion Protein
  6. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  7. Drug

    Imelasomeran

    go.drugbank.com/drugs/DB17090
    ApprovedInvestigational

    [L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922]

  8. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    [L32803] In clinical trials, vildagliptin has a relatively low risk of hypoglycemia. … , or a thiazolidinedione in patients with inadequate glycemic control following monotherapy.

    Mixtures: Vildagliptin/Metformin 1A Pharma 50 mg/850 mg – Filmtabletten, Vildagliptin/Metformin 1A Pharma 50 mg/1000 mg - FilmtablettenProducts: Vildagliptin 1A Pharma 50 mg - Tabletten
  9. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system.

  10. Drug

    Simethicone

    go.drugbank.com/drugs/DB09512
    ApprovedInvestigational

    Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. … [A228308] It has a favourable safety profile as it is not systemically absorbed.[A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308]

    Mixtures: M A L D I M, SAL DE FRUTAS LUA PLUSCategories: Compounds used in a research, industrial, or household setting